Teva Pharmaceutical (TEVA)
NYSE:TEVA
TEVA Stock Chart & Stats
$29.14
$0.18(0.83%)
At close: 4:00 PM EST
$29.14
$0.18(0.83%)
Day’s Range― - ―
52-Week Range$12.47 - $37.35
Previous CloseN/A
Volume1.13M
Average Volume (3M)7.20M
Market Cap
$33.88B
Enterprise Value$47.17B
Total Cash (Recent Filing)$3.56B
Total Debt (Recent Filing)$17.38B
Price to Earnings (P/E)25.4
Beta0.72
Next Earnings
Apr 29, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding1,164,638,700
10 Day Avg. Volume8,411,791
30 Day Avg. Volume7,198,262
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.53
Price to Sales (P/S)2.08
P/FCF Ratio31.24
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue2.73
Enterprise Value/Gross Profit5.28
Enterprise Value/Ebitda14.94
Forecast
1Y Price Target
$39.78Price Target Upside36.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)2.7
Revenue Forecast (FY)$16.66B
Bulls Say, Bears Say
Bulls Say
Branded Product DemandStronger-than-expected underlying demand for Austedo and a stable branded portfolio support a revenue base that can drive margin expansion as cost-efficiency plans are executed.
Clinical ResultsAnalyst's buy rating references clinical data showing duvakitug maintained strong efficacy with monthly maintenance dosing, suggesting a competitive profile within the TL1A class.
Partnership And R&D FundingA Royalty Pharma partnership supplies non-dilutive funding to advance the IL-15 program, lowering financing risk while preserving equity upside from future drug development.
Bears Say
Competition And Market Entry RiskPivotal trials for duvakitug are still ongoing and a first-mover competitor is expected to capture market leadership, which could limit Teva's commercial share and pricing power.
Program Development TimelineThe vitiligo program has a long development timeline, making its commercial benefits uncertain and potentially delaying any material contribution to sales.
Valuation And Report ObjectivityThe stock appears expensive versus specialty pharma peers, and disclosed business relationships between the company and report issuers could reduce confidence in bullish research and limit upside until independent clarity emerges.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $12.46 and its highest was $37.34 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $33.88B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Apr 29, 2026 which is in 35 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jan 28, 2026. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.641 by $0.319.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.54.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.96 in its last earnings report, beating expectations of $0.641. Following the earnings report the stock price went up 2.09%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teva Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.78 (36.51% Upside)
$39.78 (36.51% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 30.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 12.8%
Last 30 Days ▲ 12.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.69%
12-Months-Change
Fundamentals
Return on Equity
20.09%
Trailing 12-Months
Asset Growth
3.61%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Company Deck
TEVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong progress on the company’s Pivot to Growth: double-digit growth in key innovative brands, improved gross margins, meaningful pipeline validation and clear deleveraging progress. These positives were tempered by dependency on a $500M milestone for headline Q4 growth, a flat generics business with regional softness, near-term one-time inventory/gross-to-net effects that complicate comparability, higher OpEx pressure and persistent clinical/catalyst risk. On balance the strong commercial momentum, improving margin profile and validated pipeline catalysts outweigh the transitory one-time effects and execution risks.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$39.78
▲(36.51% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
0.49% Insiders
5.21% Mutual Funds
34.91% Other Institutional Investors
55.10% Public Companies and Individual Investors